医药生物行业报告（2026.1.19-2026.1.23）：国家统计局公布各项经济与人口数据,65岁及以上人口占比进一步提升

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Views - The report highlights the ongoing decline in the national population and birth rates, with a significant increase in the elderly population, which is expected to drive demand for home medical devices and supplies [5][21] - The report emphasizes the long-term positive trend in the innovative drug sector, supported by the strength of China's innovative drug companies in global competition [7] - The medical device sector is showing signs of improvement, with major companies reporting better performance in Q3, indicating a potential recovery in the industry [9] Summary by Relevant Sections Industry Overview - As of January 26, 2026, the closing index stands at 8623.36, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of January 19-23, 2026, the A-share pharmaceutical sector fell by 0.39%, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 0.05 percentage points [6][24] - The medical device sector is expected to attract more investment as the pressure from centralized procurement diminishes [9][30] Population and Demographics - By the end of 2025, the total population of China was 1,404.89 million, with a natural population growth rate of -2.41% [15] - The elderly population (aged 65 and above) reached 22,365 million, accounting for 15.9% of the total population, indicating a trend towards an aging society [18][20] Investment Recommendations - The report suggests focusing on companies in the elderly care medical sector, such as Yuyue Medical, Kefu Medical, and Loxin Medical, due to the anticipated increase in demand for home medical devices [5][22] - In the innovative drug sector, companies like Innovent Biologics and Kintor Pharmaceutical are highlighted as beneficiaries of the growing global participation of Chinese innovative drug firms [7][27] - For the medical device sector, companies such as Mindray and Hunan Aohua are recommended due to their improving performance and market position [9][30] Future Outlook - The report anticipates a recovery in the medical device sector as procurement policies become more reasonable and the pressure from centralized procurement decreases [30] - The innovative drug sector is expected to continue its upward trajectory, with more innovative projects anticipated in 2026 [26][28]